Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 5/2016

01-05-2016

DCE MRI of prostate cancer

Authors: Rose M. Berman, Anna M. Brown, Silvia D. Chang, Sandeep Sankineni, Meet Kadakia, Bradford J. Wood, Peter A. Pinto, Peter L. Choyke, Baris Turkbey

Published in: Abdominal Radiology | Issue 5/2016

Login to get access

Abstract

DCE MRI is an established component of multi-parametric MRI of the prostate. The sequence highlights the vascularization of cancerous lesions, allowing readers to corroborate suspicious findings on T2W and DW MRI and to note subtle lesions not visible on the other sequences. In this article, we review the technical aspects, methods of evaluation, limitations, and future perspectives of DCE MRI.
Appendix
Available only for authorised users
Literature
1.
Humphrey PA (2014) Cancers of the male reproductive organs. In: Stewart BW, Wild CP (eds) World cancer report. Lyon: World Health Organization
2.
Delongchamps NB, Singh A, Haas GP (2006) The role of prevalence in the diagnosis of prostate cancer. Cancer Control 13(3):158–168PubMed
3.
4.
Fütterer JJ, Briganti A, De Visschere P, et al. (2015) Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 68(6):1045–1053CrossRefPubMed
5.
Guo R, Cai L, Fan Y, et al. (2015) Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis. Prostate Cancer Prostatic Dis. doi:10.​1038/​PCan.​2015.​20
6.
Hoeks CM, Barentsz JO, Hambrock T, et al. (2011) Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 261:46–66CrossRefPubMed
7.
Qayyum A, Coakley FV, Lu Y, et al. (2004) Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. Am J Roentgenol 183(4):1079–1083CrossRef
8.
Hedgire SS, Eberhardt SC, Borczuk R, McDermott S, Harisinghani MG (2014) Interpretation and reporting multiparametric prostate MRI: a primer for residents and novices. Abdom Imaging. 39(5):1036–1051CrossRefPubMed
9.
Alonzi R, Padhani AR, Allen C (2007) Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 63:335–350CrossRefPubMed
10.
Tan CH, Wang J, Kundra V (2011) Diffusion weighted imaging in prostate cancer. Eur Radiol 21:593–603CrossRefPubMed
11.
Verma S, Turkbey B, Muradyan N, et al. (2012) Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. Am J Roentgenol 198(6):1277–1288CrossRef
12.
Bonekamp D, Macura KJ (2008) Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate. Top Magn Reson Imaging 19(6):273–284CrossRefPubMed
13.
Turkbey B, Mena E, Aras O, et al. (2013) Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer. Clin Oncol 25(8):451–460CrossRef
14.
Wegiel B, Bjartell A, Ekberg J, et al. (2005) A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. Oncogene 24:6385–6393PubMed
15.
Green MM, Hiley CT, Shanks JH, et al. (2007) Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 67:84–90CrossRefPubMed
16.
Mucci LA, Powolny A, Giovannucci E, et al. (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27:5627–5633CrossRefPubMedPubMedCentral
17.
Erbersdobler A, Isbarn H, Dix K, et al. (2010) Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 28:687–692CrossRefPubMed
18.
Mucci LA, Powolny A, Giovannucci E, et al. (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the Health Professionals Follow-Up Study. J Clin Oncol 27:5627–5633CrossRefPubMedPubMedCentral
19.
20.
de Bazelaire CM, Duhamel GD, Rofsky NM (2004) MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology 230(3):652–659CrossRefPubMed
21.
Sertdemir M, Schoenberg SO, Sourbron S (2013) Interscanner comparison of dynamic contrast-enhanced MRI in prostate cancer: 1.5 versus 3 T MRI. Invest Radiol 48(2):92–97CrossRefPubMed
22.
Muller BG, Kaushal A, Sankineni S, et al. (2015) Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. Urol Oncol 33(10):425.e1–425.e6CrossRef
23.
24.
Engelbrecht MR, Huisman HJ, Laheij RJ, et al. (2003) Discrimination of prostate cancer form normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 229:248–254CrossRefPubMed
25.
Girouin N, Mege-Lechevallier F, Tonina Senes A, et al. (2007) Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 17(6):1498–1509CrossRefPubMed
26.
Nicholson B, Schaeffer G, Theodorescu D (2001) Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev 20:297–319CrossRefPubMed
27.
Bigler SA, Deering RE, Brawer MK (1993) Comparison of microscopic vascularity in benign and malignant prostate tissue. Human Pathol 24:220–226CrossRef
28.
Siegal JA, Yu E, Brawer MK (1995) Topography of neovascularity in human prostate carcinoma. Cancer 75:2545–2551CrossRefPubMed
29.
Oto A, Kayhan A, Jiang Y, et al. (2010) Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 257(3):715–723CrossRefPubMed
30.
Hansford BG, Peng Y, Jiang Y, et al. (2015) Dynamic contrast-enhanced MR imaging curve-type analysis: is it helpful in the differentiation of prostate cancer from healthy peripheral zone? Radiology 275(2):448–457CrossRefPubMed
31.
Noworoslski SM, Henry RG, Vigneron DB, et al. (2005) Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI and 3D MRSI. Magn Reson Med 53:249–255CrossRef
32.
Bonekamp D, Jacobs MA, El-Khouli R, et al. (2011) Advancements in MR imaging of the prostate; from diagnosis to interventions. RadioGraphics 31(3):677–703CrossRefPubMedPubMedCentral
33.
Barentz JO, Richenberg J, Clements R, et al. (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757CrossRef
34.
Tofts PS, Brix G, Buckley DL, et al. (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 10(3):2223–2232CrossRef
35.
Van Dorsten FA, van der Graaf M, Engelbrecht MR, et al. (2004) Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 20:279–287CrossRefPubMed
36.
Knopp MV, Giesel FL, Marecos H, et al. (2001) Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 12:301–308CrossRefPubMed
37.
Futteter JJ, Engelbrecht MR, Huisman HJ, et al. (2005) Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 237:541–549CrossRef
38.
Ocak L, Bernardo M, Metzger G, et al. (2007) Dynamic contrast-enhanced MRI of prostate cancer a 3T: a study of pharmacokinetic parameters. AJR 189(849):W192–W201CrossRef
39.
Isebart S, DeKeyzer F, Haustermans K, et al. (2012) Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer correlation to whole-mount histopathology. Eur J Radiol 81:e217–e222CrossRef
40.
Rosenkrantz AB, Sabach A, Babb JS, et al. (2013) Prostate Cancer: comparison of dynamic contrast-enhanced MRI techniques for localization of peripheral zone tumor. AJR 3:W471–W478CrossRef
41.
Turkbey B, Pinto PA, Mani H, et al. (2010) Prostate cancer: value of multiparametric MR imaging at 3 T for detection—histopathologic correlation. Radiology 255:89–99CrossRefPubMedPubMedCentral
42.
Hansford BG, Karademir I, Peng Y, et al. (2014) Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol 21(5):569–577CrossRefPubMed
43.
Tan CH, Hobbs BP, Wei W, Kundra V (2015) Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. Am J Roentgenol 204:W439–W448CrossRef
44.
45.
Cha D, Kim CK, Park SY, Park JJ, Park BK (2014) Evaluation of suspected soft tissue lesion in the prostate bed after radical prostatectomy using 3T multiparametric magnetic resonance imaging. Magn Reson Imaging 33(4):407–412CrossRefPubMed
46.
Roy C, Foudi F, Charton J, et al. (2013) Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. Am J Roentgenol 200(4):W361–W368CrossRef
47.
Sciarra A, Panebianco V, Salciccia S, et al. (2008) Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 54(3):589–600CrossRefPubMed
48.
Cirillo S, Petracchini M, Scotti L, et al. (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19(3):761–769CrossRefPubMed
49.
Barrett T, Davidson S (2014) Enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post-failed external beam radiation therapy. Can Urol 8:708–714
50.
Low RN, Fuller DB, Muradyan N (2011) Dynamic gadolinium-enhanced perfusion MRI of prostate cancer: assessment of response to hypofractionated robotic stereotactic body radiation therapy. Am J Roentgenol 197(4):907–915CrossRef
51.
Vos EK, Litjens GJS, Kobus T, et al. (2013) Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol 64(3):448–455CrossRefPubMed
52.
Moradi M, Salcudean SE, Chang SD, et al. (2012) Multiparametric MRI maps for detection and grading of dominant prostate tumors. J Magn Reson Imaging 35(6):1403–1413CrossRefPubMed
53.
Turkbey B, Pinto P, Mani H, et al. (2010) Prostate cancer: value of multiparametric MR imaging at 3 T for detection—histopathologifc correlation. Radiology 255(1):89–99CrossRefPubMedPubMedCentral
54.
Franiel T, Lüdemann L, Rudolph B, et al. (2008) Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared. Investig Radiol 43(7):481–487CrossRef
55.
Aydin H, Hekimogl B, Tatar IG (2013) Limitations, disabilities, and pitfalls of dynamic contrast-enhanced MRI as a diagnostic modality in prostate cancer. Am J Roentgenol 200(3):W326CrossRef
56.
Lim C, Quon J, McInnes M, et al. (2015) Does a cleansing enema improve image quality of 3T surface coil multiparametric prostate MRI? J Magn Reson Imaging 42(3):689–697CrossRefPubMed
57.
McDonald RJ, McDonald JS, Kallmes DF, et al. (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275(3):772–782CrossRefPubMed
58.
Niaf E, Lartizien C, Bratan F, et al. (2014) Prostate focal peripheral zone lesions: characterization at multiparametric MR imaging-influence of a computer-aided diagnosis system. Radiology 271(3):761–769CrossRefPubMed
59.
Scheenen TWJ, Rosenkrantz AB, Haider MA, Fütterer JJ (2015) Multiparametric magnetic resonance imaging in prostate cancer management: current status and future perspectives. Investig Radiol . doi:10.​1097/​RLI.​0000000000000163​
60.
Wang S, Burtt K, Turkbey B, Choyke P, Summers RM (2014) Computer aided-diagnosis of prostate cancer on multiparametric MRI: a technical review of current research. BioMed Res Int 2014:789561PubMedPubMedCentral
61.
Kwak JT, Xu S, Wood BJ, et al. (2015) Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging. Med Phys 42(5):2368–2378CrossRefPubMedPubMedCentral
Metadata
Title
DCE MRI of prostate cancer
Authors
Rose M. Berman
Anna M. Brown
Silvia D. Chang
Sandeep Sankineni
Meet Kadakia
Bradford J. Wood
Peter A. Pinto
Peter L. Choyke
Baris Turkbey
Publication date
01-05-2016
Publisher
Springer US
Published in
Abdominal Radiology / Issue 5/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-015-0589-3

Other articles of this Issue 5/2016

Abdominal Radiology 5/2016 Go to the issue

OriginalPaper

Practical aspects of prostate MRI: hardware and software considerations, protocols, and patient preparation

Commentary

Commentary regarding the inter-reader reproducibility of PI-RADS version 2

OriginalPaper

The expanding landscape of diffusion-weighted MRI in prostate cancer

Pictorial Essay

Benign causes of diffusion restriction foci in the peripheral zone of the prostate: diagnosis and differential diagnosis

OriginalPaper

Why we need a vendor neutral specification for delineating prostate cancer with mpMRI

OriginalPaper

Evaluation of the impact of computed high b-value diffusion-weighted imaging on prostate cancer detection
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits